246 related articles for article (PubMed ID: 12526561)
1. Kinetics and mechanism for reduction of the anticancer prodrug trans,trans,trans-[PtCl2(OH)2(c-C6H11NH2)(NH3)] (JM335) by thiols.
Lemma K; Shi T; Elding LI
Inorg Chem; 2000 Apr; 39(8):1728-34. PubMed ID: 12526561
[TBL] [Abstract][Full Text] [Related]
2. Kinetics and mechanism for reduction of anticancer-active tetrachloroam(m)ine platinum(IV) compounds by glutathione.
Lemma K; Berglund J; Farrell N; Elding LI
J Biol Inorg Chem; 2000 Jun; 5(3):300-6. PubMed ID: 10907740
[TBL] [Abstract][Full Text] [Related]
3. Reduction of ormaplatin by an extended series of thiols unravels a remarkable correlation.
Dong J; Tian H; Song C; Shi T; Elding LI
Dalton Trans; 2018 Apr; 47(16):5548-5552. PubMed ID: 29611592
[TBL] [Abstract][Full Text] [Related]
4. Kinetics and mechanism of reactions of the drug tiopronin with platinum(IV) complexes.
Huo S; Shi H; Liu D; Shen S; Zhang J; Song C; Shi T
J Inorg Biochem; 2013 Aug; 125():9-15. PubMed ID: 23665090
[TBL] [Abstract][Full Text] [Related]
5. Oxidation of 3,6-dioxa-1,8-octanedithiol by platinum(IV) anticancer prodrug and model complex: kinetic and mechanistic studies.
Huo S; Shen S; Liu D; Shi T
J Phys Chem B; 2012 Jun; 116(22):6522-8. PubMed ID: 22574871
[TBL] [Abstract][Full Text] [Related]
6. Reduction of ormaplatin and cis-diamminetetrachloroplatinum(iv) by ascorbic acid and dominant thiols in human plasma: kinetic and mechanistic analyses.
Dong J; Ren Y; Huo S; Shen S; Xu J; Tian H; Shi T
Dalton Trans; 2016 Jul; 45(28):11326-37. PubMed ID: 27327648
[TBL] [Abstract][Full Text] [Related]
7. L-selenomethionine reduces platinum(IV) anticancer model compounds at strikingly faster rates than L-methionine.
Huo S; Dong J; Shen S; Ren Y; Song C; Xu J; Shi T
Dalton Trans; 2014 Nov; 43(41):15328-36. PubMed ID: 25075569
[TBL] [Abstract][Full Text] [Related]
8. Quantum chemical modeling of the reduction of cis-diammineplatinum(IV) tetrachloride [Pt(NH3)2Cl4] by methyl thiolate anion.
Dobrogorskaia-Méreau IaI; Nemukhin AV
J Comput Chem; 2005 Jul; 26(9):865-70. PubMed ID: 15825188
[TBL] [Abstract][Full Text] [Related]
9. Spectroscopic, kinetic, and theoretical analyses of oxidation of dl-ethionine by Pt(IV) anticancer model compounds.
Wang J; Yao H; Lu T; Dong J; Xu B; Liu Y; Liu C; Zhou L; Shi T
Spectrochim Acta A Mol Biomol Spectrosc; 2019 Dec; 223():117328. PubMed ID: 31295632
[TBL] [Abstract][Full Text] [Related]
10. Dependence of the reduction products of platinum(IV) prodrugs upon the configuration of the substrate, bulk of the carrier ligands, and nature of the reducing agent.
Sinisi M; Intini FP; Natile G
Inorg Chem; 2012 Sep; 51(18):9694-704. PubMed ID: 22921246
[TBL] [Abstract][Full Text] [Related]
11. Reduction of some Pt(IV) complexes with biologically important sulfur-donor ligands.
Jovanović S; Petrović B; Bugarčić ŽD; van Eldik R
Dalton Trans; 2013 Jun; 42(24):8890-6. PubMed ID: 23657491
[TBL] [Abstract][Full Text] [Related]
12. Reactivity of the glutathione species towards the reduction of ormaplatin (or tetraplatin).
Dong J; Huo S; Shen S; Xu J; Shi T; Elding LI
Bioorg Med Chem Lett; 2016 Sep; 26(17):4261-6. PubMed ID: 27481559
[TBL] [Abstract][Full Text] [Related]
13. Kinetic and equilibria studies of the aquation of the trinuclear platinum phase II anticancer agent [(trans-PtCl(NH(3))(2))(2)(mu-trans-Pt(NH(3))(2)(NH(2)(CH(2))(6)NH(2))(2))](4+) (BBR3464).
Davies MS; Thomas DS; Hegmans A; Berners-Price SJ; Farrell N
Inorg Chem; 2002 Mar; 41(5):1101-9. PubMed ID: 11874344
[TBL] [Abstract][Full Text] [Related]
14. Investigations of the Kinetics and Mechanism of Reduction of a Carboplatin Pt(IV) Prodrug by the Major Small-Molecule Reductants in Human Plasma.
Liu Y; Tian H; Xu L; Zhou L; Wang J; Xu B; Liu C; Elding LI; Shi T
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31726728
[TBL] [Abstract][Full Text] [Related]
15. Inversion of the cis geometry requirement for cytotoxicity in structurally novel platinum(II) complexes containing the bidentate N,O-donor pyridin-2-yl-acetate.
Bierbach U; Sabat M; Farrell N
Inorg Chem; 2000 May; 39(9):1882-90. PubMed ID: 11428108
[TBL] [Abstract][Full Text] [Related]
16. Relationships between reduction properties and cancer cell growth inhibitory activities of cis-dichloro- and cis-diiodo-Pt(IV)-ethylenediamines.
Kratochwil NA; Bednarski PJ
Arch Pharm (Weinheim); 1999 Aug; 332(8):279-85. PubMed ID: 10489538
[TBL] [Abstract][Full Text] [Related]
17. Equilibrium and kinetic studies of the aquation of the dinuclear platinum complex [[trans-PtCl(NH3)2]2(mu-NH2(CH2)6NH2)]2+: pKa determinations of aqua ligands via [1H,15N] NMR spectroscopy.
Davies MS; Cox JW; Berners-Price SJ; Barklage W; Qu Y; Farrell N
Inorg Chem; 2000 Apr; 39(8):1710-5. PubMed ID: 12526558
[TBL] [Abstract][Full Text] [Related]
18. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.
Kelland LR; Barnard CF; Mellish KJ; Jones M; Goddard PM; Valenti M; Bryant A; Murrer BA; Harrap KR
Cancer Res; 1994 Nov; 54(21):5618-22. PubMed ID: 7923207
[TBL] [Abstract][Full Text] [Related]
19. Importance of platinum(II)-assisted platinum(IV) substitution for the oxidation of guanosine derivatives by platinum(IV) complexes.
Choi S; Vastag L; Larrabee YC; Personick ML; Schaberg KB; Fowler BJ; Sandwick RK; Rawji G
Inorg Chem; 2008 Feb; 47(4):1352-60. PubMed ID: 18220340
[TBL] [Abstract][Full Text] [Related]
20. Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum(IV) complex.
O'Neill CF; Ormerod MG; Robertson D; Titley JC; Cumber-Walsweer Y; Kelland LR
Br J Cancer; 1996 Oct; 74(7):1037-45. PubMed ID: 8855971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
